MAGABI presents a poster in the 7th EFB (European Bioanalysis Forum) in the LC-MS/MS Bioanalysis area (Title: Simultaneous determination of Cyproterone Acetate (CPA) and Ethinylestradiol (EE) in human plasma using on-line extraction and high-performance liquid chromatography coupled to mass spectrometry)
MAGABI starts providing the market with two new analytical services: analysis for cleaning validation (residual analysis) and drug stability trials.
MAGABI presents 2 posters in the SIMCRO (Brazilian Symposium on Chromatrography and Related Techniques) in Bioanalysis (Title: A very simple and fast method for quantification of Temozolomide in human plasma by LC-MS/MS) and in Pharmaceutical Analysis (Title: Determination of SUMA SUPERSOL® residue by LC-MS/MS – Application for a cleaning validation process).
MAGABI presents the lecture BE/BA in Brazil: Past, Present and Future Perspectives in the Symposium on Clinical and Pharmaceutical Solutions through Analysis (CPSA Brazil 2014)
MAGABI collaborates with discussions of the Quantitative Bioanalytical Methods Validation and Implementation: The 2013 Revised FDA Guidance, an event organized by FDA (Food and Drug Administration) and AAPS (American Association of Pharmaceutical Scientists), in order to discuss FDA's new guide draft for Bioanalytical Methods Validation.
In the same month, participates in the 5th Br-Mass Congress, organized by the Brazilian Society of Mass Spetrometry, presenting the poster Simultaneous determination of rosuvastatin (RVT) and ezetimibe (EZT) in human plasma using liquid-liquid extraction and high-performance liquid chromatography coupled to mass spectrometry: Application to a bioequivalence study.
Conduction of four Bioequivalence studies (Analytical Phase) for Colombia.
MAGABI premises are transferred to Itapevi, in the Great São Paulo. The change allows the laboratory to diversify the services provided, not only in Bioanalysis but also in pharmaceutical researches.
The new laboratory in Itapevi (SP), especially designed to house the analytical operations performed by MAGABI, is approved by Anvisa (National Health Surveilance Agency).
2011 and 2012
MAGABI is part of the Global Analysis Consortium, a global consortium that gathers representatives from the pharmaceutical industry, regulatory bodies and the world's leading research centers, in order to identify, discuss and harmonize the best practices in bioanalysis among all participating countries.
MAGABI is successfully approved in their first international audit, performed by WHO (World Health Organization), on an oral contraceptive study for Chile.
Bioequivalence (Analytical Phase) international study for Uruguay is concluded.
First MAGABI's Bioequivalence international study (Analytical Phase of oral contraceptive) for Chile.
MAGABI completes the Analytical Phase of Bioequivalence study for nasal spray. The laboratory is the first to develop and validate such methodology in Brazil.
MAGABI conducts for the fist time an Pre-clinical study for an innovative medicine, from analysis of veterinary biological material.
MAGABI completes the Analytical Phase of Bioequivalence study for oral contraceptive.
MAGABI is the first laboratory in Brazil to develop and validate a methodology for quantification of LC-MS/MS biological samples in oral contraceptive hormone studies.
MAGABI receives Anvisa's Primary Certification in Good Practices on Bioequivalence / Relative Bioavailability.
MAGABI is founded.